Knowles Julius sold KROS
November 21, 2025 · Form 4 insider transaction
Knowles Julius sold 130,494 shares of Keros Therapeutics, Inc. at $17.75 per share, a transaction worth $2.32M. The trade was recorded as disposition to the issuer and disclosed on an SEC Form 4, filed 27 days after the transaction.
Footnotes
Represents shares tendered and accepted for purchase by the Issuer in a cash tender offer commenced by the Issuer on October 20, 2025. The Issuer announced the final results of the tender offer on November 20, 2025.; The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II.